The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn. As a penny stock with a market cap of just $600 million, falls squarely in the high-risk, high-reward category. The firm has also seen success providing AI tools and partnership to other players in the biotech and pharma space, including major pl ...

Accessibility StatementSkip Navigation SINGAPORE, Oct. 2, 2025 /PRNewswire/ --Â On October 2, 2025, NYB announced that it entered into a business combination agreement ("BCA") with RF Acquisition Corp II ("RFAI") (NASDAQ: RFAI), a publicly traded special purpose acquisition company, in a transaction aimed at making NYB become a publicly listed company (the "Proposed Transaction"). Following the closing, the combined company (the "Combined Company") is expected to be listed on Nasdaq under the reserved ticke ...